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Elizabeth Levitis,1 Jacob W. Vogel,1 Thomas Funck,1 Vladimir Hachinski,2
Serge Gauthier,3 Jonathan Vöglein,4,5,6 Johannes Levin,4 Brian A. Gordon,7
Tammie Benzinger,7 Yasser Iturria-Medina,1† Alan C. Evans,1† for the Dominantly Inherited
Alzheimer Network* and for the Alzheimer’s Disease Neuroimaging Initiative**
†These authors contributed equally to this work.
*Data used in preparation of this article were obtained from the Dominantly Inherited Alzheimer’s Network (DIAN) database
(cnda.wustl.edu). As such, the investigators within the DIAN contributed to the design and implementation of DIAN and/or
provided data but did not participate in analysis or writing of this report. A complete listing of DIAN investigators can be found
in the supplemental section.
**Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or
provided data but did not participate in analysis or writing of this report.
A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/
ADNI_Authorship_List.pdf.

Amyloid-beta deposition is one of the hallmark pathologies in both sporadic Alzheimer’s disease and autosomal-dominant Alzheimer’s
disease, the latter of which is caused by mutations in genes involved in amyloid-beta processing. Despite amyloid-beta deposition being a
centrepiece to both sporadic Alzheimer’s disease and autosomal-dominant Alzheimer’s disease, some differences between these
Alzheimer’s disease subtypes have been observed with respect to the spatial pattern of amyloid-beta. Previous work has shown that
the spatial pattern of amyloid-beta in individuals spanning the sporadic Alzheimer’s disease spectrum can be reproduced with high accuracy using an epidemic spreading model which simulates the diffusion of amyloid-beta across neuronal connections and is constrained
by individual rates of amyloid-beta production and clearance. However, it has not been investigated whether amyloid-beta deposition in
the rarer autosomal-dominant Alzheimer’s disease can be modelled in the same way, and if so, how congruent the spreading patterns of
amyloid-beta across sporadic Alzheimer’s disease and autosomal-dominant Alzheimer’s disease are. We leverage the epidemic spreading
model as a data-driven approach to probe individual-level variation in the spreading patterns of amyloid-beta across three different largescale imaging datasets (2 sporadic Alzheimer’s disease, 1 autosomal-dominant Alzheimer’s disease). We applied the epidemic spreading
model separately to the Alzheimer’s Disease Neuroimaging initiative (n = 737), the Open Access Series of Imaging Studies (n = 510) and
the Dominantly Inherited Alzheimer’s Network (n = 249), the latter two of which were processed using an identical pipeline. We assessed
inter- and intra-individual model performance in each dataset separately and further identiﬁed the most likely subject-speciﬁc epicentre of
amyloid-beta spread. Using epicentres deﬁned in previous work in sporadic Alzheimer’s disease, the epidemic spreading model provided
moderate prediction of the regional pattern of amyloid-beta deposition across all three datasets. We further ﬁnd that, whilst the most
likely epicentre for most amyloid-beta–positive subjects overlaps with the default mode network, 13% of autosomal-dominant
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Alzheimer’s disease individuals were best characterized by a striatal origin of amyloid-beta spread. These subjects were also distinguished
by being younger than autosomal-dominant Alzheimer’s disease subjects with a default mode network amyloid-beta origin, despite having a similar estimated age of symptom onset. Together, our results suggest that most autosomal-dominant Alzheimer’s disease patients
express amyloid-beta spreading patterns similar to those of sporadic Alzheimer’s disease, but that there may be a subset of autosomaldominant Alzheimer’s disease patients with a separate, striatal phenotype.
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PiB binding. Interestingly, PiB binding in the cortex was
found to be lower in ADAD mutation carriers than agematched subjects with probable sAD.10 Whilst the sample
size of this study was small (n = 30 ADAD mutation carriers,
n = 30 sAD subjects), the ﬁndings suggest that the most
probable area(s) of earliest amyloid-beta accumulation
may not be homogenous amongst all ADAD mutation
carriers.
Recently, an event-based model of disease progression
was applied to ADAD mutation carriers. The authors found
that the biomarker likeliest to exhibit the earliest deviation
from normal levels was a cortical amyloid-beta deposition
measure, followed by amyloid-beta deposition in the caudate, putamen, accumbens and thalamus.11 In sAD, a separate
model leveraged cerebrospinal ﬂuid (CSF) and amyloid-beta
signals to stage subjects according to amyloid-beta accumulation status. In this study, subjects who were both CSF and
amyloid-beta negative according to a set of data-driven
thresholds were deemed to be non-accumulators, whereas
those who were CSF positive but amyloid-beta negative
were deemed to be early amyloid-beta accumulators.12
Regions pinpointed as areas of earliest accumulation were
those that had signiﬁcantly increased amyloid-beta signal in
early accumulators compared with non-accumulators.
According to this system, the precuneus, medial orbitofrontal
cortex and posterior cingulate (PC) were all categorized as regions of early accumulation, whereas the caudal anterior cingulate (CAC) was pinpointed as an area of intermediate
accumulation. Together, these studies suggest possible differences between ADAD and sAD in the earliest regions to accumulate amyloid-beta.
Whilst both data-driven approaches can be used to glean
the order in which biomarkers can be detected at either a regional or global level, neither of them is mechanistic in nature. To better understand how amyloid-beta or tau
spreads in the brain, we can instead turn to an epidemic
spreading model (ESM) developed to stochastically reproduce the propagation and deposition of misfolded proteins
such as amyloid-beta, tau and alpha-synuclein. The overarching nonlinear differential equation of the model posits
that the change in misfolded protein deposition in each
macroscopic region of interest (ROI) is equal to the probability of endogenously producing and exogenously receiving
misfolded proteins from connected ROIs, minus the probability of clearing the deposited misfolded proteins. This approach has previously been applied to model the spread of
amyloid-beta and tau across anatomical connections in individuals along the sAD spectrum.13,14 When applied to over
700 subjects in the ADNI dataset, the ESM was able to explain 46–57% of the variance in the mean regional amyloid-beta deposition probabilities of the distinct clinical
subgroups and identiﬁed the posterior and anterior cingulate
cortices as the seed regions of amyloid-beta propagation.
These seed regions are in agreement with what has been established in the literature.15 Using the ESM, we can evaluate
whether there is sufﬁcient evidence to suggest that amyloidbeta spreads along neuronal connections in ADAD as well.
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To date, there is no cure for Alzheimer’s disease (AD), the
principal neurodegenerative cause of dementia. Treating patients with dementia is costly—in 2009, the average cost for a
patient with AD was roughly 57 000 USD.1 The socioeconomic gravity of treating AD has spurred research seeking to prevent or mitigate AD by ﬁrst developing
biomarkers that can be used for early diagnosis and monitoring.2 The two main pathological signs of AD are neuroﬁbrillary tau tangles and amyloid-beta senile plaques, and both
are required to deﬁnitively conﬁrm AD at autopsy.3 Most
hypothetical models of AD progression have been rooted
in the amyloid cascade hypothesis, which posits that excessive amounts of soluble amyloid-beta cause a buildup of insoluble amyloid-beta, disrupting synaptic function and
accelerating tau hyperphosphorylation.4 The majority of
AD cases are sporadic in nature, and the much rarer autosomal dominant form of AD is caused by mutations in
genes—namely, APP, PSEN1, PSEN2—that impact the processing of the amyloid precursor protein from which the
amyloid-beta peptide is cleaved. Whilst ample research has
pointed to accumulation of amyloid-beta in the brain as
being one of the earliest pathological biomarkers in both
sporadic Alzheimer’s disease (sAD) and autosomaldominant Alzheimer’s disease (ADAD), we know quite little
about where and how amyloid-beta begins to accumulate,
how it spreads in the brain and whether either of these is variable across individuals.
amyloid-beta is purported to spread trans-neuronally—
along neuronal connections—in a prion-like fashion as opposed to spreading locally in the extracellular space.5
Earlier evidence of this mechanism came from the animal
model literature where infused amyloid-beta was shown to
travel between neurones across neuronal ﬁbres.6
Computational modelling quantitatively comparing the
two modes of spread has lent further support to the transneuronal spread as the more likely mechanism via which
amyloid-beta propagates throughout the brain.7 An ADAD
mutation virtually guarantees amyloidosis, making carriers
of these mutations incredibly important for the study of
amyloid-related processes and brain changes in AD.
However, it is still unclear just how similar ADAD and
sAD are with respect to the progression of various biomarkers, including amyloid-beta.
In general, most studies in this domain have focused less
on inter-individual variability and have primarily reported
group differences. Unlike in sAD, where amyloid-beta deposition is highest in neocortical areas, several groups have reported signiﬁcantly increased striatal, thalamic and
neocortical amyloid-beta deposition in ADAD mutation carriers compared with noncarriers.8,9 One study evaluating
differences between the presenilin 1 (PSEN1), presenilin 2
(PSEN2) and amyloid precursor protein (APP) ADAD mutation types found that all mutation types had high striatal PiB
binding, whilst some mutation carriers had higher cortical
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Furthermore, we can evaluate how similar ADAD and sAD
are with respect to which regions amyloid-beta begins
spreading from. We tackle this question by applying the
ESM within three different datasets representing sAD and
ADAD, to both evaluate differences between ADAD and
sAD, as well as validate the previously published results in
an independent dataset.

Methods
Participants for this study are comprised of individuals from
three multi-centre studies: the Dominantly Inherited
Alzheimer Network (DIAN; https://dian.wustl.edu), the
Alzheimer’s Disease Neuroimaging Initiative (ADNI; http://
adni.loni.usc.edu) and the Open Access Series of Imaging
Studies (OASIS; www.oasis-brains.org). Whilst the ESM
had already been applied to ADNI, a dataset representative
of LOAD, we include an additional dataset for two reasons
—(i) to validate the previously published results in an independent cohort and (ii) to compare results in DIAN with a
dataset that used the same radiotracer and was processed
using the same pipeline.
The DIAN dataset represents individuals from families
known to have mutations in the APP, PSEN1 and PSEN2
genes. Both mutation carriers and non-carriers were used
for different stages of the analysis. We selected individuals
who had at least one PIB positron emission tomography
(PET) scan and accompanying T1w scan from the 12th semiannual DIAN data freeze. For this study, DIAN serves as the
dataset representative of ADAD.
The OASIS dataset is a compilation of participants from
multiple studies, and the participants range from older, cognitively normal adults to those at various stages of cognitive
decline and dementia.

MRI and PET acquisition and
preprocessing
MRI and PET acquisition procedures for the DIAN,16 ADNI
(http://adni.loni.usc.edu/methods/), and OASIS17 datasets
have previously been described in detail.
It is important to note that the processing pipeline and the
radiotracer for the ADNI dataset diverge from those used for
DIAN and OASIS. One of the overarching goals of this study
was to test model robustness both across datasets and across
methodologies. The multi-cohort design of our study allows
us to (i) compare ESM performance in ADAD (DIAN) to
sAD (OASIS) where both datasets were acquired using the
same radiotracer and processed using the same pipeline
and (ii) ascertain whether the results reported in the original
ESM publication for ADNI could be replicated in a second
sAD dataset using a different pipeline.
For ADNI, the preprocessing pipeline is taken from the
original ESM publication.13 Brieﬂy, individual AV45 PET

scans were acquired and processed in the following order
—dynamic co-registration, averaging across time, resampling and reorientation from native space to a standard
voxel space, spatial ﬁltering and ﬁnally spatial normalization
to MNI space. For the DIAN and OASIS dataset, wholebrain T1w scans and individual PiB-PET scans were acquired. Quality control was performed as per the ADNI
protocol. FreeSurfer version 5.3 (http://surfer.nmr.mgh.
harvard.edu) was used to derive subject-speciﬁc segmentations corresponding to regions in the Desikan–Killiany–
Tourville atlas (DKT).18 Only cortical and subcortical regions overlapping with the Mindboggle DKT atlas were
used, for a total of 78 regions.19
For both OASIS and DIAN, the PET Uniﬁed Pipeline
(PUP; https://github.com/ysu001/PUP) was used to preprocess the PET scans. The processing steps used include
smoothing, interframe motion correction and co-registration.
Speciﬁcally, PET images in the 4dfp format are smoothed to
achieve a common spatial resolution of 8 mm to minimize
inter-scanner differences.20 PET-MR registration was performed using a vector-gradient algorithm (VGM).21
Co-registered summed PET scans in the 4dfp ﬁle format
were downloaded from the CNDA portal (https://cnda.
wustl.edu), and 4dfp images were subsequently converted
to the Nifti ﬁle format for further analysis.

Regional amyloid-beta probabilities
Traditionally, static PET processing involves quantifying
co-registered PET images using standardized uptake value ratios (SUVR) for each ROI with respect to the average signal in
a reference region devoid of speciﬁc tracer binding. The reference region typically used in AD amyloid-beta PET imaging
studies is the cerebellar cortex; however, amyloid deposition
has been observed in the cerebellar cortex of individuals
with ADAD.22 Based on recent work seeking to clarify the
optimal reference region for amyloid-beta measurement
using PiB-PET and the DIAN cohort, we used the brainstem
as the reference region for the DIAN and OASIS datasets.23,24 For the ADNI dataset, we used the amyloid-beta
deposition probabilities that had previously been generated
(using a cerebellar reference region).13
The original ESM paper introduced a voxelwise probability metric to calculate amyloid-beta deposition probabilities.
For each subject, this approach creates a bootstrapped sampling consisting of 40 000 subsamples in the 5–95% of values
in the reference region. Subsequently, an extreme value distribution (EVD) is created using the maximum value observed
in each bootstrapped sample. The EVD is used to create an extreme cumulative distribution function, and for each voxel in
the PET image, the probability of it being greater than every
value in the EVD is computed. A ﬁnal regional amyloid-beta
deposition probability is calculated as the average of the
probabilities corresponding to each voxel within a given
ROI. Given the overall higher PiB-PET signal in the brainstem
than the cerebellar cortex, we use the 75th percentile value
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Table 1 Demographic information
DIAN
Dataset
n
Age (SD)
% Women
EYO (SD)
% ApoE4
% amyloid-beta positive
% Cognitively normal

T1
249
39.01 (10.7)
56.3%
−8.54 (10.9)
30.1%
55%
68.7%

T2
124
42.12 (9.7)
60.1%
−4.7 (9.8)
29.53%
63.7%
58.8%

ADNI

OASIS

737
72.43 (7.2)
44.9%
NA
51.7%
54%
26.2%

510
67.65 (9.8)
57.8%
NA
NA
25%
86.5%

rather than the maximum in each bootstrap sampling to create the EVD when using the brainstem as the reference region.
For the DIAN dataset, we observed that noncarriers’ amyloid-beta deposition probabilities were negligible in all ROIs
except for the globus pallidus and thalamus, ROIs that
have previously been observed to have nonspeciﬁc uptake
of PiB.25,26 Given their young age (Table 1), we are conﬁdent
that the DIAN non carriers are truly amyloid-negative and
are therefore a fully reliable control group. Subsequently,
for each ROI, across all available timepoints, the noncarriers’
signal was used to create a ROI-speciﬁc control distribution.
For each mutation carrier, we calculated a Z-score for their
amyloid-beta binding probability in the ROI with respect to
the ROI-speciﬁc control distribution. Within each ROI, we
min–max scaled the absolute values of the z-scored signal
across all timepoints to have probabilities in the [0,1] range
again.

Epidemic spreading model
The spread of amyloid-beta was simulated using the ESM, a
diffusion model that has previously been used to simulate the
spread of amyloid-beta and tau in the ADNI dataset from an
initial epicentre(s) and through an ROI network.13,14 In addition to the connectivity between ROIs, subject-speciﬁc
propagation parameters inﬂuence the magnitude or extent
of the spreading pattern. These parameters correspond to a
global clearance rate, global production rate and age of onset. These are ﬁt by solving a non-linear differential equation
designed to reproduce the overall regional pattern of amyloid-beta deposition. The ESM is ﬁt by searching the parameter space, and the set of parameters that yield the regional
pattern of amyloid-beta deposition most like the reference
(observed) pattern is selected.
The main data input to the ESM is the ROI by Subject
matrix reﬂecting regional amyloid-beta deposition probabilities for each subject. Epicentres can either be supplied
by the user or selected in a data-driven way. In the datadriven context, the ROI or combination of ROIs that
best explain the average group-level pattern are returned
as the epicentres. For a more detailed overview of the
equations underlying the ESM, please refer to the original
publication.13

Connectivity measures
In order to propagate amyloid-beta signal across the brain,
the ESM requires a matrix of pairwise relationships between
ROIs. This informs the ﬁnal regional pattern of amyloidbeta. Earlier applications of the ESM tested whether amyloid-beta spreads along synapses by using a structural connectivity matrix.
We used a structural connectivity matrix derived from diffusion spectrum imaging (DSI) scans of 60 young healthy
subjects from the CMU-60 DSI template.27 The acquisition
and pre-processing steps have been described in detail in
the original ESM paper and were based on methodology
developed in an earlier paper.28 Brieﬂy, all images were
non-linearly co-registered to MNI space, and orientation distribution functions (ODFs) representing nerve ﬁbre orientations were calculated. All intravoxel ﬁbre ODF maps were
averaged to create an ODF template, and an automated ﬁbre
tractography method was used to calculate probabilistic
axonal connectivity values for each voxel and the surface
of each grey matter region in the DKT atlas. Previously described anatomical connection probabilities were then generated for each ROI–ROI pair.

amyloid-beta positivity
The ESM has previously been shown to be sensitive to spurious levels of signal, so we opted to conﬁne our analysis to
amyloid-beta positive subjects.14 We used Gaussian mixture
modelling (GMM) to compute amyloid-beta positivity
thresholds in a data-driven way for both the PUP generated
SUVRs and the probability values averaged across a composite set of regions that are implicated in AD. Speciﬁcally,
these include the bilateral precuneus, superior frontal, rostral middle frontal, lateral orbitofrontal, medial orbitofrontal, superior temporal and middle temporal ROIs.
For each metric, we ﬁt a two-component mixture model
across the entire DIAN dataset—including non-carriers
and mutation carriers—and estimated a cut-off. Only subjects who were positive on both the SUVR and probability
metrics were considered amyloid-beta positive for subsequent analyses. Since the DIAN and OASIS datasets were
both processed using the WUSTL PUP, we applied the cut-
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offs generated using the DIAN dataset to the OASIS dataset
as well. amyloid-beta positive subjects in these datasets
were deﬁned as those whose average amyloid-beta value
across a set of previously deﬁned cortical areas surpassed
0.81 and 0.01236 for SUVR and deposition probability values, respectively. We illustrate the correspondence between within-subject composite amyloid-beta SUVRs and
deposition probabilities, as well as the GMM results in
Supplementary Fig. 1. amyloid-beta positive ADNI subjects were identiﬁed using a previously deﬁned composite
amyloid-beta SUVR threshold of 1.11.

Using the structural connectivity matrix and the crosssectional baseline subject by region amyloid-beta probability
deposition matrix, we ﬁt the ESM across different possible
epicentres for the DIAN, ADNI, and OASIS datasets.
Model performance for each experiment was evaluated by
mean within-subject and global ﬁt. Within-subject performance
is evaluated as the Pearson r2 between the subject-speciﬁc observed and predicted regional amyloid-beta deposition probabilities measured using PiB-PET. We evaluate global ﬁt by
averaging the observed and predicted regional amyloidbeta probabilities across all subjects, respectively, and calculating the Pearson r2 between the averaged observed and predicted patterns. To ensure that our results are statistically
signiﬁcant and speciﬁc to the connectivity matrix we used,
we scrambled the original connectivity matrix 100 times
whilst preserving degree and strength distributions using
the Brain Connectivity Toolbox (https://sites.google.com/
site/bctnet/). We used the null distribution of the mean
within-subject ﬁt and global ﬁt to calculate the mean and
95% conﬁdence intervals (CIs) for each ESM experiment.
Building off previous results suggesting that amyloid-beta
ﬁrst accumulates in the PC and CAC and subsequently
spreads to other regions in the brain (in ADNI), we sought
to evaluate whether this ﬁnding replicates in another
LOAD dataset, as well as the DIAN dataset. Given our objective of evaluating whether a cortical or striatal epicentre
better explains amyloid-beta spreading patterns in ADAD,
we repeated this analysis for all three datasets using the caudate and putamen as the seed regions.
For a more data-driven approach to epicentre selection, in
each dataset, we evaluated global ﬁt using each bilateral
ROI as an independent epicentre. For each subject we noted
the epicentre that provided the best within-subject ﬁt, and
we assessed how frequently speciﬁc epicentres were present
within each dataset. Given the lack of consensus about
whether ADAD mutation carriers ﬁrst accumulate amyloidbeta in the striatum or neocortical regions that overlap with
the default mode network, we further divided the possible epicentres into three subgroups—default mode network (DMN),
striatum, and other. ROIs falling into the DMN group included the PC, cAC, rostral anterior cingulate, precuneus,
and medial orbitofrontal cortex. The striatum subgroup included the caudate and putamen, and the other group

Data availability
OASIS-3 and ADNI are open access datasets for which
access can be obtained at https://www.oasis-brains.org/
and http://adni.loni.usc.edu/data-samples/access-data/, respectively. The DIAN data can be obtained by request
through application, and more information about requesting data access can be found here https://dian.wustl.edu/
our-research/for-investigators/dian-observational-studyinvestigator-resources/data-request-terms-and-instructions/.

Code availability
The Matlab code for the ESM has been made available as a
public software release with an accompanying paper
(neuropm-lab.com/software29). All the Python code used to
analyze ESM results, perform statistical analysis, and visualize results can be found at https://github.com/llevitis/DIAN_
ESM_AmyloidBeta_Project.git.

Results
Sample information
Baseline PiB-PET scans measuring ﬁbrillar amyloid-beta
load were available for 249 ADAD mutation carriers in the
DIAN dataset. One-hundred twenty-four of these mutation
carriers had one follow-up PiB-PET scan, and 44 of them
had two follow-up scans. Baseline AV45-PET scans were
available for 737 individuals from the ADNI dataset, and
baseline PiB-PET scans were available for 510 individuals
from the OASIS cohort. Demographic information for these
samples can be found in Table 1.
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Statistical analysis

contained all ROIs not in the other two subgroups. Using
these data-driven epicentre subgroups, we compared withinsubject model performance using either the caudate and putamen or CAC + PC as epicentres across the epicentre subgroups. We evaluated the statistical difference in the models’
performance across epicentre subgroups using the nonparametric Kolmogorov-Smirnov (K-S) test statistic.
After stratifying subjects across epicentre subgroups
(DMN, Striatum and Other), we examined associations
with age and EYO. We additionally ran ordinary least-squares
general linear models (GLMs) to assess the relationship between the epicentre subgroup and the amyloid-beta signal in
all ROIs whilst covarying for age and sex. We FDR corrected
the relationships using the Benjamini–Hochberg approach.
We additionally ran a multinomial logistic regression model
to compare the ‘Other’, ‘DMN’ and ‘Striatum’ epicentre subgroups within the amyloid positive DIAN sample, given that
the other datasets did not have any individuals who fell into
the ‘Striatum’ epicentre sub-group. The covariates used were
sex, CDR, age, and education.
As a follow-up, we evaluated the test-retest reliability of
the best within-subject epicentre for each subject that had
two scans in the DIAN dataset.

Amyloid-beta spread in autosomal dominant AD
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Putative areas of early amyloid-beta
accumulation in LOAD do not explain
the full picture in ADAD
To evaluate whether neuronal connectivity can explain the
whole-brain pattern of amyloid-beta in both ADAD mutation carriers and individuals from the OASIS dataset, we ﬁt
the ESM to regional amyloid-beta deposition probabilities
derived using PiB-PET or AV45-PET data (see ‘Methods’
section).
We ﬁrst evaluated how well previously identiﬁed regions of
early amyloid, namely cingulate and striatal regions, recapitulate group-level whole-brain amyloid-beta patterns across all
three datasets. We will refer to the model using the CAC and
PC as epicentres as the CAC + PC model, and the one using
the caudate and putamen as the striatal model. In the DIAN dataset, the model using the CAC and PC as seed regions explained 27% (null model mean r2 [95% CI] = 0.119 [0.089,
0.164]; P , 0.01) of the aggregated pattern of amyloid-beta,

and on average explained 14.6% (null model mean r2 [95%
CI] = 0.07 [0.002, 0.179]; P = 0.1) of the regional pattern of
amyloid-beta within individual subjects (Fig 1A). In amyloidbeta positive subjects, the global ﬁt and the mean within subject
ﬁt improved to 31% and 20.7% (P , 0.05), respectively. When
stratifying performance across the three main mutation types,
we found that there was no signiﬁcant difference between the
three groups.
In line with the results that had been previously shown for
the ADNI dataset in,13 the CAC + PC model explained
53.9% (null model mean r2 [95% CI] = 0.103 [0.074,
0.148]; P , 0.01) of the aggregated pattern of amyloidbeta and on average explained 39.1% (null model mean r2
[95% CI] = 0.087 [0.002, 0.217]; P , 0.01) of the regional
pattern of amyloid-beta in individual subjects. In amyloidbeta positive subjects, the global ﬁt and the mean within subject ﬁt changed slightly to 51% and 38%, respectively.
In the LOAD validation dataset, OASIS, the performance
was lower than what had previously been reported for
ADNI. Across the whole dataset, the CAC + PC model

Downloaded from https://academic.oup.com/braincomms/article/4/3/fcac085/6567551 by guest on 24 October 2022

Figure 1 Comparison of global model ﬁt across datasets and epicentres. ESM performance (global ﬁt) across the ADNI, OASIS and
DIAN datasets using either the (A) PC and caudal anterior cingulate or (B) caudate and putamen as epicentres. Each dot represents the observed
and predicted mean signal for an ROI across all subjects within a dataset. Only amyloid-beta positive subjects were included.
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explained 28% (null model mean r2 [95% CI] = 0.158
[0.123, 0.217]; P , 0.01) of the aggregated pattern of amyloid-beta and on average explained 9% (null model mean r2
[95% CI] = 0.063 [0.017, 0.139]; P = 0.15) of the within
subject variance. However, when we only look at amyloidbeta positive individuals, the global ﬁt and the average within subject ﬁt increased to 40% (null model mean r2 [95% CI]
= 0.14 [0.098,0.18]; P , 0.01) and 21% (null model mean r2
[95% CI] = 0.082 [0.002, 0.196]; P = 0.04), respectively,
and the results were signiﬁcant.
Since a primary goal of this study was to identify whether
a cortical or striatal epicentre better explains the regional
patterns of amyloid-beta in DIAN, we additionally repeated
the same analysis using the caudate and putamen as the seed
regions (Fig. 1B). When applied to ADNI, the striatal model
performed poorly. It explained 3% (null model mean r2
[95% CI] = 0.055 [0.043, 0.072]; P = 1) of the aggregated
pattern of amyloid-beta and on average explained 5% (null
model mean r2 [95% CI] = 0.05 [0.001, 0.139]; P = 0.5) of
the within-subject amyloid-beta patterns in amyloid-beta
positive subjects. In DIAN amyloid-beta positive subjects,
the striatal model explained 18% (null model mean r2

[95% CI] = 0.103 [0.072, 0.146]; P , 0.02) of the aggregated pattern of amyloid-beta and on average explained
17.2% (null model mean r2 [95% CI] = 0.085 [0.001,
0.256]; P = 0.04) of the within-subject pattern. In amyloid-beta+ OASIS subjects, the striatal model explained
14%
(null
model
mean
r2
[95%
CI] =
0.084 [0.062, 0.133]; P , 0.02) and on average 11.4%
(null model mean r2 [95% CI] = 0.059 [0.001, 0.16]; P =
0.15) of the global and within-subject results, respectively.

Epicentre heterogeneity in DIAN
compared with ADNI and OASIS
We initially compared ESM performance between the ADNI
and DIAN dataset using a priori deﬁned epicentres. Next, we
ran the ESM using each bilateral ROI as the model epicentre
to evaluate which ROI best explains the whole-brain patterns of amyloid-beta in each dataset. We assigned each participant to an epicentre subgroup based on which ROI
yielded the best within-subject performance.
In Fig. 2A and B, we show the relative breakdown of epicentre subgroups within the datasets in all subjects, and in
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Figure 2 Epicentre frequency and within-subject performance across all datasets. (A) Epicentre frequency across all subjects in each
dataset. (B) The same information when only amyloid-beta positive subjects are included from each dataset and epicentre group, using only
amyloid-beta positive subjects. (C) The ESM within-subject performance is shown using the CAC and posterior cingulate as epicentres. (D) The
ESM within-subject performance is shown using the caudate and putamen as epicentres.
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amyloid-beta positive subjects only. In amyloid-beta positive
subjects from ADNI and OASIS, 89.2% of amyloid-beta
positive ADNI subjects and 72.7% of amyloid-beta positive
OASIS subjects have a DMN epicentre, whilst the remaining
subjects fall into the Other category. In the DIAN dataset,
there was substantially more heterogeneity, with 59.1% of
amyloid-beta subjects falling into the DMN group, 13.1%
into the striatum group, and 27.7% into the Other group.
We next assessed the performance of the ESM in each ‘epicentre subgroup’ across different model epicentres. We hypothesized that ESM within-subject ﬁt using the caudate
and putamen as epicentres would be highest within the
DIAN striatum epicentre subgroup, and this was substantiated by the results (Fig. 2B). Encouragingly, we found that
the ESM within-subject ﬁt using the CAC and PC as epicentres was highest in the DMN epicentre subgroups across all
the datasets, and it remained high in the Other subgroup
for ADNI. The CAC + PC model ﬁt continued to be higher
in ADNI than OASIS (KS = 0.42, P = 1.6e-12) and DIAN
(KS = 0.41, P = 7.3e-11) within the DMN groups. Within
the DIAN dataset, the striatal model signiﬁcantly outperformed the CAC + PC model in the striatal epicentre subgroup (KS = 0.67, P = 2.15e-4).

Epicentre subgroup in DIAN
associated with distinct whole-brain
amyloid-beta patterns and age at
symptom onset
Next, we were interested in parsing the heterogeneity observed within the DIAN dataset with respect to best within-

subject epicentre. Speciﬁcally, we sought to evaluate any
differences in whole brain amyloid-beta pattern and
demographics.
As expected, we reafﬁrmed that individuals in the Other
subgroup had signiﬁcantly lower global cortical amyloidbeta-PET signal (Fig. 3A), suggesting these subjects to be
‘false positives’. In other words, individuals with ‘Other’
(i.e. not DMN or striatal) epicentres tended to be low amyloid amyloid-beta+ individuals, for whom the model was
likely ﬁtting non-speciﬁc or off-target binding.
We further examined whole-brain amyloid-beta pattern
differences amongst the different epicentre groups.
Individuals whose whole-brain amyloid-beta patterns are
best described using a DMN epicentre have more amyloidbeta in the cortex compared with individuals in the other
two groups (FDR , 0.05; Fig. 3B). Conversely, individuals
in the Other epicentre subgroup had less amyloid-beta everywhere in the brain. Individuals with striatal epicentres
showed greater striatal PiB binding, but reduced binding in
occipital and lateral temporoparietal cortex.
The epicentre groups were also associated with differences
in age. Speciﬁcally, whilst the DMN and striatum group did
not differ with respect to EYO, individuals in the striatum
group were younger than those in the DMN group
(Fig. 3C). This may potentially suggest that the striatal epicentre phenotype is associated with a younger age at symptom onset and/or an altered disease time course. We
additionally assessed differences between the epicentre subgroups in DIAN using a multinomial logistic regression model. The multinomial model replicated our previous ﬁnding
that age signiﬁcantly contributed to an individual having a

Downloaded from https://academic.oup.com/braincomms/article/4/3/fcac085/6567551 by guest on 24 October 2022

Figure 3 Demographic differences across epicentre subgroups in DIAN (only amyloid-beta positive individuals). (A)
Within-subject amyloid-beta composite signal across the epicentre subgroups. (B) Comparison of whole-brain amyloid-beta signal across the
epicentre sub-groups. Regions are colour-coded based on their t-value for the particular group, with red indicating that there is more amyloid-beta
signal in the respective group compared with the other two groups. (C) Within-subject EYO and age differences across the epicentre subgroups
were compared using a Mann–Whitney–Wilcoxon test. There were no signiﬁcant differences for age whereas the DMN group was signiﬁcantly
older than the striatum and other group (DMN versus striatum: U = 1091, P = 0.003; DMN versus other: U = 2089, P = 0.005 two-tailed with
Bonferoni correction).
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versus timepoint 2 (T2). Values along the diagonal represent individuals who remain the same epicentre subgroup at visits 1 and 2. (B) Swarm plot
representing composite amyloid-beta change in each T1/T2 epicentre subgroup combination.

DMN or Striatum epicentre, with age being lower in the
Striatum group. The Other epicentre subgroup was also
younger and more educated than the DMN group. For the
DMN-Striatum and DMN-Other comparisons, we report
the z test statistics across the covariates in Supplementary
Table 1.

Epicentre reliability across
timepoints
With the availability of longitudinal PiB-PET data for a subset of our dataset, we were able to assess how reliably the
ESM selects an individual’s epicentre subgroup when presented with data from subsequent timepoints. As shown in
Table 1, 124 of the DIAN mutation carriers had two timepoints available, and 44 had three available.
Subjects with a DMN or Other epicentre at timepoint 1
(T1) almost always stay that way at timepoint 2 (T2), whilst
there is more variability amongst subjects with a striatal epicentre at T1. This may perhaps indicate that some individuals with a striatal epicentre at T1 are in a temporally
short-lived phase whereby amyloid-beta ﬁrst begins accumulating in the striatum and subsequently in the DMN. In other
words, individuals who are advancing with respect to amyloid-beta accumulation may ﬁrst either show amyloid-beta in
the striatum, the striatum then the DMN, or initially in the
DMN.
To address this issue of conversion from a striatal
epicentre to a different epicentre, we assessed change in composite amyloid-beta deposition probabilities across the different T1–T2 epicentre combinations. We ﬁnd that
individuals who persist with either a striatum or DMN epicentre, or switch from a striatal to DMN epicentre, are

gaining amyloid over time (Fig. 4B). We observe that those
who switch from a DMN or a striatal epicentre to an
‘Other’ are exhibiting a loss of amyloid-beta signal, possibly
due to cortical atrophy.

Discussion
Throughout this study, we have explored how well a model
that simulates the transneuronal spread of amyloid-beta under biologically feasible constraints of amyloid-beta production and clearance can explain regional amyloid-beta
probabilities for subjects who are either along the sAD or
ADAD continuum. Whilst many cross-sectional studies
have attempted to elucidate differences in the regional amyloid-beta patterns across these subtypes of Alzheimer’s disease, the present study provides a direct comparison of
hypothetical spreading patterns of amyloid-beta using a
mechanistic model.
The ESM generates within subject trajectories of amyloidbeta accumulation, and we leveraged this to assess potential
heterogeneity across subjects with respect to the earliest locations of amyloid-beta. Several earlier PiB-PET studies in
ADAD have compared which areas begin to accumulate
amyloid-beta earliest in the disease time courses of ADAD
and LOAD. These studies have reported signiﬁcantly more
amyloid in the striatum in presymptomatic ADAD versus
presymptomatic LOAD,8 and it has been suggested that different mutation types may contribute to heterogeneity
amongst individuals with ADAD.10,30 We found that there
was a portion of subjects in the DIAN dataset whose regional
amyloid-beta patterns were best reproduced using a striatal
epicentre. All but two of these subjects were amyloid-beta
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Figure 4 Evaluating epicentre reliability across timepoints in DIAN. (A) Confusion matrix for epicentre subgroups at timepoint 1 (T1)
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the spread of amyloid-beta over a static network reﬂecting
anatomical connectivity in health, these results, along with
those from a separate study evaluating the sequence of
changes in anatomical connectivity in elderly individuals’
brains over the course of sAD progression,35 suggest that
amyloid-beta affects the circuits or networks via which it
spreads.
One objective of this study was to reproduce the ﬁndings
in13 in an independent dataset. One of the issues we observed
when modelling group-level results was that of a signiﬁcant
disparity in overall amyloid-beta levels across the three datasets. In particular, the OASIS dataset had a high percentage
of younger, cognitively normal adults who were amyloidbeta negative. As we discussed in the Results section, the
ESM appears to be sensitive to low levels of amyloid-beta
—i.e. the ESM is ﬁt to non-speciﬁc or off-target signal not reﬂecting true pathology, and this would have a particularly
large impact on within-subject results for the most likely epicentre(s). As such, we opted to focus on amyloid-beta positive subjects for the within-subject analyses. When we
limited our analysis to amyloid-beta subjects, we found
that the results across ADNI and OASIS were on par with
one another, with a vast majority of subjects being best described by an epicentre that overlaps with the default mode
network. This observation is in line with previous data driven approaches used in both cross-sectional and longitudinal
studies to discern which regions begin to show increased
amyloid-beta in early stage sAD.35,36
This study has several limitations that pertain to measurement of amyloid-beta, anatomical connectivity and the ESM
methodology. One limitation faced when directly comparing
the ADNI and DIAN sets is that the PET data was collected
using the AV45 radiotracer in ADNI and the PiB tracer in
DIAN/OASIS. Additionally, we sought to use the results in
the original ESM publication as a benchmark, and this required using the derivatives that had been produced for
that paper. Both OASIS and DIAN had been processed using
PUP, and there were subsequently differences in the way that
the PET scans were corrected for motion and co-registered to
the MRI scans. As had been reported in,14 there are many different choices that can be made in a PET data processing
pipeline and the connectivity matrix, and the downstream effects include variable model ﬁt. To determine the best epicentre and by extension epicentre subgroup for each
subject, we selected the bilateral ROI that yielded the best
within-subject ﬁt, but this method ignores potentially close
values across ROIs.
Despite these limitations, our study made several important advances. We show that the majority of amyloid-beta
positive subjects in three independent datasets had wholebrain amyloid-beta patterns best reproduced using epicentres overlapping with the DMN. The presence of the younger
striatal epicentre subgroup in only the DIAN dataset supports the importance of analyzing differences in individual
trajectories, as variability in ADAD disease courses may
have important implications for efforts to reduce amyloidbeta burden and improve cognitive impairment.
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positive, suggesting that the results were not driven by false
positive signal. Furthermore, these subjects could be distinguished from those with a DMN epicentre by their younger
age and younger age of symptom onset, lending support to
the idea that this group represents an ADAD-speciﬁc phenotype distinct from one characterized by initial amyloid-beta
spread from ROIs in the DMN. However, one of the difﬁculties with interpreting this result lies in the small percentage of
subjects with a best ﬁtting striatal epicentre. It is difﬁcult to
disentangle whether this striatal epicentre group is truly a
separate group for whom amyloid-beta deﬁnitively begins
accumulating solely in the striatum, or the result of these subjects being imaged during a short dynamic time period, or
perhaps both. We also found that, in the DIAN dataset, individuals in the ‘Other’ epicentre subgroup were more educated than the DMN subgroup. Given that the ‘Other’
epicentre group had less amyloid, this ﬁnding supports previous literature showing a potential protective effect of education on amyloid accumulation in ADAD individuals.31
However, not all subjects’ amyloid-beta patterns were
best recapitulated using a striatal epicentre, and this was supported by the group-level ﬁndings. Whilst a hypothetical striatal epicentre explained more variance in the DIAN dataset
than in both the ADNI dataset and our validation dataset,
OASIS, a DMN epicentre still explained more variance in
DIAN within the entire amyloid-beta positive cohort. This
may suggest that the amyloid-beta pattern proﬁles are not
homogeneous amongst ADAD mutation carriers and that
there are individuals who are more similar to sAD patients
with respect to amyloid-beta. We were able to address this
in part by showing that there is a subgroup of DIAN participants whose amyloid-beta patterns are explained as well as
the ADNI cohort’s when using the caudal anterior cingulate
and PC as epicentres.
Our ﬁndings provide data-driven corroboration of a
neuropathological study ﬁnding that ADAD mutation carriers have increased striatal vulnerability to accumulate
amyloid-beta due to the regional distribution and metabolism of APP.32 The same study showed an increased accumulation of striatal tau in ADAD mutation carriers compared
with sAD individuals, and previous simulations of tau
spreading in sAD shed additional light on how amyloidbeta facilitates the spread of tau and inﬂuences its spatial localization.14 In tandem, a study in ADAD has indicated that
striatal amyloid is a better predictor than cortical amyloid of
both tauopathy and cognitive decline in ADAD mutation
carriers.33 With availability of tau-PET data for the DIAN
cohort, it would be worthwhile to assess this relationship
whilst accounting for the epicentre subgroup differences.
In light of mounting evidence for striatal and networklevel involvement in ADAD, both with respect to amyloidbeta and tau, a recent study found that frontostriatal circuits
are structurally and functionally impacted by APP and
PSEN1 mutations.34 Speciﬁcally, the APP gene increased
functional connectivity and altered axonal integrity in the
caudate to rostral middle frontal gyrus tract. Whilst the
ESM and other mechanistic spreading models reproduce
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